EGFR and non-small cell lung carcinoma: Because of the promising results of EGFR inhibitors in animal models of HCC and their efficacy in other solid human tumors such as non-small cell lung carcinomas and colorectal cancers [180,181,182], it was hypothesized that targeting the EGFR signaling pathway might be beneficial also in HCC.